[바이오타임즈] GC Green Cross announced that it has launched diabetes treatment ‘Neodapa Tab.’
‘Neodapa Tab.’ is an SGLT-2 inhibitor-type diabetes treatment containing dapagliflozin. In particular, ‘Neodapa Tab.’ It is expected that it will be easy to
Dapagliflozin is one of the SGLT-2 inhibitors, a drug used to treat type 2 diabetes. It inhibits SGLT-2 in the kidney to reduce glucose reabsorption and excretes glucose through urine, thereby lowering blood sugar.
This drug is administered as an adjunct to diet and exercise therapy to improve blood sugar control in patients with type 2 diabetes. It can be used to lower blood sugar in all stages of type 2 diabetes except those with moderate or severe chronic kidney disease.
‘Folmindapa extended-release tablet’ is a combination drug that combines dapagliflozin and metformin.
Metformin blocks glucose production in the liver and reduces glucose absorption in the intestine, improving sensitivity to insulin, and is represented as a first-choice drug in the treatment of diabetes. Additional hypoglycemic effect was demonstrated when dapagliflozin and metformin were used in patients with insufficient blood sugar control despite taking metformin.
An official from GC Green Cross said, “Starting with the release of this diabetes treatment, we will continue to add diabetes treatment lineups to establish ourselves as a strong player in the domestic diabetes treatment market, which is estimated to be worth 1 trillion won.”
[바이오타임즈=정민아 기자] news@biotimes.co.kr
